Teresa Tarrago

At Telara Pharma, we develop innovative therapies based on cilastatin, a drug with a solid safety record and a powerful neuroprotective effect on the retina. Our goal is to transform glaucoma and diabetic retinopathy retreatments through a strategy that targets retinal neurodegeneration and inflammation—two key processes that current medicine does not address. Unlike therapies focused solely on reducing intraocular pressure (IOP), our ophthalmic drops directly protect retinal ganglion cells, preserving vision and quality of life.

https://www.cesif.es/

https://iqs.edu/es/

Accure Therapeutics is a R&D pharma company dedicated to developing innovative medicines to treat patients suffering from Central nervous system (CNS) diseases, a major medical challenge. https://accure.health/

𝗧𝗵𝗲 𝗕𝗶𝗼𝗘𝘅𝗽𝗲𝗿𝘁 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 𝗶𝘀 𝗮 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝗼𝗳 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝘀𝗲𝗰𝘁𝗼𝗿𝘀 𝗼𝗳 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 - Evaluated innovative start-up projects in the biotech and pharmaceutical industries to identify life sciences initiatives with the right potential and business plan for investment. - Reviewed pitch decks, conducted market research, and provided scientific advice to help companies develop their business (digital health, medical devices, and diagnostics sectors.

Analyse early stage concepts, evaluate, mentor, technology transfer, business strategy, clinical strategy, and operations. BHV (Barcelona Health Ventures) is a start-up builder in the digital health/medical device/biotech space.

Beyond You is an RNA-Seq & Artificial Intelligence solution to improve people's performance, health and nutrition. Through the sequencing of the RNA and the subsequent treatment of the data, a dashboard is generated with all the information related to the alteration of the metabolic pathways of the individuals analyzed in order to offer to the doctor a tool to improve and validate their intervention methodology to their patients.

Oversee daily operations of company with 15 staff focused on developing and licensing new drugs. Participate in pharmaceutical and biotech industry conferences. Guide and execute due diligence procedures to complete new business agreements. Seek and liaise with potential angel investors and venture capitalists in Europe and US. • Directed discovery programs and preclinical development of two medicines. • Designed and implemented cost-efficient business. • Formed and maintained international partnership with The Academic Medical Center, Netherlands; German Center for Neurodegenerative Diseases, Germany; Nencki Institute of Experimental Biology, Poland; and Epilepsy Therapy Screening Program, National Institute for Health, USA. • Secured 3M€ financing round series with European investors and 3.5M€ from local, EU, and U.S. public institutions. • Filed three patent applications. • Named Top 10 Young European Biotech Entrepreneurs by #Labiotech.eu, 2019. • Selected as Best Innovative Company "Senén Vilaro" Award, University of Barcelona, 2017. • Chaired 1st Barcelona Peptide Therapeutics Symposium, Spain, 2017. • Recognized as Best Biotechnology Project, EXPOQUIMIA Award, 2014.

The Collider is the Venture Builder program by Mobile World Capital Barcelona that addresses the challenge of transforming scientific knowledge into technological solutions. From this pioneering program, it connects the results of scientific research with the entrepreneurial initiative in order to create highly innovative technological startups.